As pharmaceutical import tariffs take shape in Europe, President Donald Trump is rounding out the week by spotlighting ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Evotec has inked a deal to sell its biologics manufacturing facility in Toulouse, France, to generics giant Sandoz for around ...

As with the NMOSD-focused film, “Rare Connections in gMG” is aimed at countering the “relatively low” awareness of the rare disease, according to Christophe Hotermans, M.D., Ph.D., Alexion’s head of ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple ...